BISPECIFIC ANTI-CD3 ANTIBODIES, BISPECIFIC ACTIVATABLE ANTI-CD3 ANTIBODIES, AND METHODS OF USING THE SAME
The invention relates generally to antibodies, activatable antibodies, multispecific antibodies, and multispecific activatable antibodies that specifically bind to at least CD3, as well as to methods of making and using these antibodies, activatable antibodies, multispecific antibodies, and/or multispecific activatable antibodies in a variety of therapeutic, diagnostic and prophylactic indications.
1 . An activatable anti-CD3ε antibody (AB) linked to a cleavable moiety (CM) that is a substrate for a protease and a masking moiety (MM),
wherein the activatable anti-CD3ε antibody has a structural arrangement from N-terminus to C-terminus as follows: MM-CM-AB or AB-CM-MM, and
wherein the MM has one or more of the following characteristics selected from the group consisting of:
(a) a dissociation constant (K d ) for binding to the activatable anti-CD3e antibody that is no more than 2-fold greater than the K d for binding of the activatable anti-CD3ε antibody to CD3ε;
(b) an affinity for binding to the activatable anti-CD3ε antibody that is 2-fold less than the affinity of binding of the activatable anti-CD3ε antibody to CD3ε;
(c) reduces the ability of the activatable anti-CD3ε antibody to bind CD3ε by at least 90% in an in vitro target displacement assay; and
(d) comprises an amino acid sequence selected from the group consisting of SEQ ID NO: 371, SEQ ID NO: 372, SEQ ID NO: 373, SEQ ID NO: 374, SEQ ID NO: 375, SEQ ID NO: 376, SEQ ID NO: 377, SEQ ID NO: 378, SEQ ID NO: 379, SEQ ID NO: 380, SEQ ID NO: 381, SEQ ID NO: 382, SEQ ID NO: 383, SEQ ID NO: 384, SEQ ID NO: 385, SEQ ID NO: 386, SEQ ID NO: 387, SEQ ID NO: 388, SEQ ID NO: 389, SEQ ID NO: 390 and SEQ ID NO: 391.
2 . The activatable anti-CD3ε AB of claim 1 , wherein the MM has a K d for binding to the activatable anti-CD3e antibody that is no more than 2-fold greater than the K d for binding of the activatable anti-CD3ε antibody to CD3ε.
3 . The activatable anti-CD3ε AB of claim 1 , wherein the MM has an affinity for binding to the activatable anti-CD3ε antibody that is 2-fold less than the affinity of binding of the activatable anti-CD3ε antibody to CD3ε.
4 . The activatable anti-CD3ε AB of claim 1 , wherein the MM reduces the ability of the activatable anti-CD3ε antibody to bind CD3ε by at least 90% in an in vitro target displacement assay.
5 . The activatable anti-CD3ε AB of claim 1 , wherein the MM comprises an amino acid sequence selected from the group consisting of SEQ ID NO: 371, SEQ ID NO: 372, SEQ ID NO: 373, SEQ ID NO: 374, SEQ ID NO: 375, SEQ ID NO: 376, SEQ ID NO: 377, SEQ ID NO: 378, SEQ ID NO: 379, SEQ ID NO: 380, SEQ ID NO: 381, SEQ ID NO: 382, SEQ ID NO: 383, SEQ ID NO: 384, SEQ ID NO: 385, SEQ ID NO: 386, SEQ ID NO: 387, SEQ ID NO: 388, SEQ ID NO: 389, SEQ ID NO: 390 and SEQ ID NO: 391.
6 . The activatable anti-CD3ε AB of claim 1 , wherein the CM is a polypeptide of up to 15 amino acids in length.
7 . The activatable anti-CD3ε AB of claim 1 , wherein the CM is positioned in the activatable anti-CD3ε antibody such that binding of the activatable anti-CD3ε antibody to CD3ε is reduced to having a dissociation constant that is at least 20-fold greater than the dissociation constant of the anti-CD3ε antibody binding to CD3ε when the anti-CD3ε antibody is not linked to the CM and MM.
8 . The activatable anti-CD3ε AB of claim 1 , wherein the MM reduces the ability of the activatable anti-CD3ε antibody to bind CD3ε by at least 90% in an in vitro target displacement assay.
9 . The activatable anti-CD3ε AB of claim 1 , wherein the MM reduces the ability of the activatable anti-CD3e antibody to bind CD3ε such that the dissociation constant (K d ) of the activatable anti-CD3e antibody when coupled to the MM towards CD3ε is at least 20 times greater than the K d of the activatable anti-CD3ε antibody when not coupled to the MM towards CD3ε.
10 . An activatable anti-CD3ε antibody (AB) linked to a cleavable moiety (CM) that is a substrate for a protease and a masking moiety (MM),
wherein the activatable anti-CD3ε antibody has a structural arrangement from N-terminus to C-terminus as follows: MM-CM-AB or AB-CM-MM, and
wherein the activatable anti-CD3e antibody has one or more of the following characteristics selected from the group consisting of:
(a) the MM has a dissociation constant (K d ) for binding to the activatable anti-CD3ε antibody that is no more than 2-fold greater than the K d for binding of the activatable anti-CD3ε antibody to CD3ε;
(b) the MM has an affinity for binding to the activatable anti-CD3ε antibody that is 2-fold less than the affinity of binding of the activatable anti-CD3e antibody to CD3ε;
(c) the MM reduces the ability of the activatable anti-CD3ε antibody to bind CD3ε by at least 90% in an in vitro target displacement assay;
(d) the MM reduces the ability of the activatable anti-CD3e antibody to bind CD3ε such that the dissociation constant (K d ) of the activatable anti-CD3e antibody when coupled to the MM towards CD3ε is at least 20 times greater than the K d of the activatable anti-CD3ε antibody when not coupled to the MM towards CD3ε;
(e) the MM reduces the ability of the activatable anti-CD3ε antibody to bind CD3ε by at least 90% in an in vitro target displacement assay; and
(f) the CM is positioned in the activatable anti-CD3ε antibody such that binding of the activatable anti-CD3ε antibody to CD3ε is reduced to having a dissociation constant that is at least 20-fold greater than the dissociation constant of the anti-CD3ε antibody binding to CD3ε when the anti-CD3ε antibody is not linked to the CM and MM.
11 . The activatable anti-CD3ε AB of claim 10 , wherein the MM has a K d for binding to the activatable anti-CD3ε antibody that is no more than 2-fold greater than the K d for binding of the activatable anti-CD3ε antibody to CD3ε.
12 . The activatable anti-CD3ε AB of claim 10 , wherein the MM has an affinity for binding to the activatable anti-CD3ε antibody that is 2-fold less than the affinity of binding of the activatable anti-CD3e antibody to CD3ε.
13 . The activatable anti-CD3ε AB of claim 10 , wherein the MM reduces the ability of the activatable anti-CD3ε antibody to bind CD3ε by at least 90% in an in vitro target displacement assay.
14 . The activatable anti-CD3ε AB of claim 10 , wherein the MM reduces the ability of the activatable anti-CD3e antibody to bind CD3ε such that the dissociation constant (K d ) of the activatable anti-CD3e antibody when coupled to the MM towards CD3ε is at least 20 times greater than the K d of the activatable anti-CD3ε antibody when not coupled to the MM towards CD3ε.
15 . The activatable anti-CD3ε AB of claim 10 , wherein the MM reduces the ability of the activatable anti-CD3ε antibody to bind CD3ε by at least 90% in an in vitro target displacement assay.
16 . The activatable anti-CD3ε AB of claim 10 , wherein the CM is positioned in the activatable anti-CD3ε antibody such that binding of the activatable anti-CD3ε antibody to CD3ε is reduced to having a dissociation constant that is at least 20-fold greater than the dissociation constant of the anti-CD3ε antibody binding to CD3ε when the anti-CD3ε antibody is not linked to the CM and MM.
17 . The activatable anti-CD3ε AB of claim 10 , wherein the MM comprises an amino acid sequence selected from the group consisting of SEQ ID NO: 371, SEQ ID NO: 372, SEQ ID NO: 373, SEQ ID NO: 374, SEQ ID NO: 375, SEQ ID NO: 376, SEQ ID NO: 377, SEQ ID NO: 378, SEQ ID NO: 379, SEQ ID NO: 380, SEQ ID NO: 381, SEQ ID NO: 382, SEQ ID NO: 383, SEQ ID NO: 384, SEQ ID NO: 385, SEQ ID NO: 386, SEQ ID NO: 387, SEQ ID NO: 388, SEQ ID NO: 389, SEQ ID NO: 390 and SEQ ID NO: 391.
18 . The activatable anti-CD3ε AB of claim 10 , wherein the CM comprises an amino acid sequence selected from the group consisting of SEQ ID NO: 67-86, 321-341, and 896-926.
19 . The activatable anti-CD3ε AB of claim 10 , further comprising a linking peptide between the MM and the CM.
20 . The activatable anti-CD3ε AB of claim 19 , wherein the linking peptide is 1 to 20 amino acids in length.
21 . The activatable anti-CD3ε AB of claim 10 , wherein the activatable anti-CD3ε antibody has a structural arrangement from N-terminus to C-terminus as follows: MM-CM-AB.
22 . The activatable anti-CD3ε AB of claim 10 , wherein the activatable anti-CD3ε antibody has a structural arrangement from N-terminus to C-terminus as follows: AB-CM-MM.
23 . A composition comprising the activatable anti-CD3ε AB of claim 1 and a carrier.
24 . A nucleic acid encoding the activatable anti-CD3ε AB of claim 1 .
25 . An expression vector comprising nucleic acid of claim 24 .
26 . A method of producing an activatable anti-CD3ε AB, the method comprising culturing a cell comprising the expression vector of claim 25 to express the activatable anti-CD3ε AB.
27 . A composition comprising the activatable anti-CD3ε AB of claim 10 and a carrier.
28 . A nucleic acid encoding the activatable anti-CD3ε AB of claim 10 .
29 . An expression vector comprising nucleic acid of claim 28 .
30 . A method of producing an activatable anti-CD3ε AB, the method comprising culturing a cell comprising the expression vector of claim 29 to express the activatable anti-CD3ε AB.